STATEMENT BY 340B HEALTH INTERIM PRESIDENT AND CEO MAUREEN TESTONI REGARDING PROPOSAL TO ENFORCE DRUG INDUSTRY TRANSPARENCY RULES
WASHINGTON, D.C.— “We are encouraged that, in response to our lawsuit, the government has proposed to begin enforcing rules demanding transparency and accountability for pharmaceutical manufacturers participating in 340B. In response to our legal challenge, HHS is now proposing to begin enforcement of the rule on Jan. 1. This would protect 340B providers from overcharges that sap them of their ability to care for patients in need. Now HHS must ensure that date does not slip.”
“These rules were ordered by Congress more than eight years ago based on clear, documented evidence of overcharging by drug companies of 340B hospitals, clinics, and health centers. The time for delay is over and now it is time for action.”
“With these rules in place, we also call on the Health Resources and Services Administration (HRSA) to create a secure website containing the ceiling prices for all 340B-eligible drugs as quickly as possible. Without this information, 340B providers cannot know if they are being charged the correct price under the law.”
“The 340B program is a key element of the national healthcare safety net. Savings from price discounts on many outpatient drugs allow 340B hospitals to serve more patients, including those who are uninsured or underinsured, and to offer vital services including trauma care, care for people with HIV/AIDS and those who are suffering from substance abuse, including opioid dependency. 340B does not cost the American taxpayers one dime.”
Contact: Richard Sorian at email@example.com or 202-536-2285.